Fact CheckerSign in

NCT07885904Not yet recruiting

Preventive Effectiveness of Primary Care Physician-led CGM-supported Comprehensive Intervention on Cardio-metabolic-immune Diseases in Community Patients With Type 2 Diabetes (Community Diabetes Control Project)

Preventive Effectiveness of Primary Care Physician-led CGM-supported Comprehensive Intervention on Cardio-metabolic-immune Diseases in Community Patients With Type 2 Diabetes (Community Diabetes Control Project) -A Cluster Randomized, Open-label, Controlled Trial

Source: ClinicalTrials.gov · Last updated 21 Oct 2026

Brief summary (registry, in English)

This community-based trial evaluates whether primary care physicians, equipped with continuous glucose monitoring (CGM) and trained under a standardized protocol with specialist backup, can improve diabetes outcomes through integrated "medication + exercise + diet" interventions. Unlike traditional fingerstick testing, CGM reveals full glycemic variability, enabling personalized, real-time adjustments. The study hypothesizes that this approach will lower HbA1c, reduce hypoglycemia risk, and decrease long-term cardiovascular, endocrine, and immune-related complications. With low-cost, reliable Chinese-made CGM devices, the intervention is safe and scalable. A cost-effectiveness analysis will also assess its public health value.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
15400 (estimated)
First submitted
14 Sept 2026
Start date
30 Nov 2026
Primary completion date
30 Jun 2030
Lead sponsor
Xiangya Hospital of Central South University
NCT number
NCT07885904

What you commit to

  • Study type: Interventional
  • Planned participants: 15400
  • From 30 Nov 2026 to the primary completion date, 30 Jun 2030
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Prior definite myocardial infarction, ischemic stroke, hemorrhagic stroke, or hospitalization for heart failure
  • Definite active immunodeficiency disease or immune-mediated inflammatory disease, or use of systemic glucocorticoids, conventional disease-modifying antirheumatic drugs, biologics, or targeted immunotherapies within 6 months before enrollment. Examples include systemic lupus erythematosus, rheumatoid arthritis, psoriasis or psoriatic arthritis, inflammatory bowel disease, Sjogren syndrome, systemic sclerosis, systemic vasculitis, autoimmune hepatitis, inflammatory myopathies, and active or thyroid-function-unstable Hashimoto thyroiditis or Graves disease
  • Concurrent malignant tumor or severe systemic disease with an estimated life expectancy \<90 days
  • Participation in another interventional clinical study within 30 days before randomization or current participation in another interventional clinical study

Other illness

  • Type 1 diabetes, specific types of diabetes, or gestational diabetes
  • History of severe allergy to CGM sensor materials, such as medical adhesive tape
  • Severe mental disorder or dementia that precludes completion of informed consent and follow-up procedures
  • Other conditions deemed by the investigator to make participation unsuitable

Lab values

  • Known severe hepatic or renal insufficiency, or dialysis for any cause. Severe hepatic insufficiency includes alanine aminotransferase (ALT) \>3 times the upper limit of normal or aspartate aminotransferase (AST) \>3 times the upper limit of normal. Severe renal insufficiency is defined as serum creatinine \>3.0 mg/dL (265.2 micromol/L) or glomerular filtration rate (GFR) \<30 mL/min/1.73 m2

Other

  • Hyperglycemic crisis, diabetic ketoacidosis, or severe hypoglycemic coma requiring assistance within the past 3 months
  • Definite diagnosis of severe diabetic complications documented in the medical history or medical records
  • Pregnancy, breastfeeding, or planned pregnancy within 90 days

Who the study is looking for

  • Aged 18-80 years, either sex
  • Permanent community residents (residing in the community for at least 6 months per year on average)
  • Baseline HbA1c 7.0%-14%, fasting blood glucose \<13.9 mmol/L, and 2-hour postprandial blood glucose \<16.7 mmol/L
  • Own and able to use a smartphone, or have assistance from family members
  • Enrolled in the National Basic Medical Insurance scheme (Urban and Rural Resident Medical Insurance or Employee Medical Insurance)
  • Participants and their legal representatives are able and willing to sign the informed consent form

Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Xiangya Hospital
Coordinator of this site? Confirm its status
ChangshaChinaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.